期刊文献+

非布司他联合别嘌醇治疗慢性肾脏病伴高尿酸血症的疗效与安全性 被引量:29

Efficacy and Safety of Febuxostat Combined with Allopurinol in Treatment of Chronic Kidney Disease Accompanied with Hypercuricemia
下载PDF
导出
摘要 目的:探讨非布司他联合别嘌醇治疗慢性肾脏病伴高尿酸血症的疗效与安全性。方法:选取2014年1月—2016年7月河南省新县人民医院收治的慢性肾脏病伴高尿酸血症患者186例作为研究对象,以随机数字表法分为观察组和对照组,每组93例。对照组患者给予别嘌醇治疗,观察组患者在对照组的基础上加用非布司他治疗。观察两组患者的临床疗效及血尿酸、血肌酐、尿素氮水平、肾小球滤过率估算值,比较两组患者不良反应发生情况的差异。结果:观察组患者的总有效率为96.77%(90/93),明显优于对照组的86.02%(80/93);治疗后,观察组患者血尿酸、血肌酐、尿素氮水平明显低于对照组;治疗4、8、12、24周后,观察组患者肾小球滤过率估算值明显低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:非布司他联合别嘌醇治疗慢性肾脏病伴高尿酸血症的疗效显著,起效快,可改善患者血尿酸指标。 OBJECTIVE: To probe into the efficacy and safety of febuxostat combined with allopurinol in treatment of chronic kidney disease accompanied with hypercuricemia. METHODS: 186 patients with chronic kidney disease accompanied with hypercuricemia admitted into the People's Hospital of Xinxian from Jan. 2014 to Jul. 2016 were selected and divided into observation group and control group via random number table,with 93 cases in each group.The control group was treated with allopurinol,while the observation group was given febuxostat combined with allopurinol. The clinical efficacy,levels of blood uric acid,serum creatinine,urea nitrogen,estimated value of glomerular filtration rate( e GFR) of two groups were observed,and the difference of incidence of adverse drug reactions between two groups were compared. RESULTS: The total effective rate of observation group( 96. 77%,90/93) was significantly higher than that of the control group( 86. 02%,80/93); after treatment,levels of blood uric acid,serum creatinine and urea nitrogen of observation group were significantly lower than those of the control group; 4 weeks,8 weeks,12 weeks,24 weeks after treatment,the e GFR of observation group was significantly lower than that of the control group,with statistically significant difference( P〈 0. 05). There was no significant difference in the incidence of adverse reactions between two groups( P 〉0. 05). CONCLUSIONS: The efficacy of febuxostat combined with allopurinol in treatment of chronic kidney disease accompanied with hypercuricemia is remarkable and taking effect rapidly,which can improve blood uric acid index.
出处 《中国医院用药评价与分析》 2017年第7期892-894,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 慢性肾脏病 高尿酸血症 非布司他 别嘌醇 Chronic kidney disease Hyperuricemia Febuxostat Allopurinol
  • 引文网络
  • 相关文献

参考文献15

二级参考文献204

  • 1张宛哲,舒礼良,王建生,赵瑛瑛.别嘌醇治疗慢性肾衰竭合并高尿酸血症患者的疗效及对UA、Cr、BUN水平的影响[J].中国老年学杂志,2014,34(7):1848-1849. 被引量:10
  • 2α酮酸制剂在肾内科应用专家协作组.慢性肾脏病蛋白营养治疗共识[J].中华肾脏病杂志,2005,21(7):421-424. 被引量:135
  • 3苗志敏,赵世华,王颜刚,李长贵,王忠超,陈颖,陈新焰,阎胜利.山东沿海居民高尿酸血症及痛风的流行病学调查[J].中华内分泌代谢杂志,2006,22(5):421-425. 被引量:207
  • 4黎磊石,刘志红主编.中国肾脏病学[M].北京:人民军医出版社,2008,1328-1338
  • 5王雪君,沈建国.小剂量苯溴马隆与别嘌醇治疗高尿酸血症60例疗效观察[J].中国现代应用药学,2007,24(4):337-339. 被引量:11
  • 6OKAMOTO K, EGER BT, NISHINO T, et al. An extremely po- tent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition[J]. J Bi- ol Chem, 2003, 278(3) : 1848 -1855.
  • 7BECKER MA, KISICKI J, KHOSRAVAN R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xan-thine oxidase, is safe and decreases serum urate in healthy volunteers [ J] Nucleosides Nucleotides Nucleic Acids, 2004,23 ( 8 - 9 ) : 1111 - 1116.
  • 8TAKANO Y, HASE-AOKI K, HORIUCHI H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/ xanthine dehydrogenase[ J]. Life Sci, 2005, 76 ( 16 ) : 1835 - 1847.
  • 9SCHUMACHER HR JR. Febuxostat: a non-purine, selective in- hibitor of xanthine oxidase for the management of hyperurieaemia in patients with gout [ J]. Expert Opin Investig Drugs, 2005,14 (7) :893 -903.
  • 10KOMORIYA K, HOSHIDE S, TAKEDA K, et al. Pharmacoki- netics and pharmacodynamics of febuxostat ( TMX-67 ) , a non- purine selective inhibitor of xanthine oxidase/xanthine dehydro- genase (NPSIXO) in patients with gout and/or hyperuricemia [ J]. Nucleosides Nucleotides Nucleic Acids, 2004, 23 ( 8 - 9 ) : 1119 - 1122.

共引文献204

同被引文献170

引证文献29

二级引证文献128

;
使用帮助 返回顶部